This year's Lasker Clinical Research Award goes to James Baird Glen for the discovery and development of the anesthetic propofol. Patients benefit from its fast onset and rapid systemic clearance, eliminating the prolonged sedation effects experienced with earlier agents. In just 30 years, propofol has been adopted around the world for safe and controlled induction of anesthesia.
Throughout human history, medical specialists and caregivers have searched for agents that induce loss of consciousness to help patients deal with pain whether in the service of surgery, tolerance of dental work, recovery from injuries incurred in the course of ordinary living, or treating the sequelae of war. The Wood LibraryMuseum of anesthesiology in Schaumberg, Illinois, named for Dr. Paul Wood, a doyen of American anesthesiology spanning the 19 th and 20 th centuries, documents efforts to ameliorate pain starting in 4000 BCE (https://www. woodlibrarymuseum.org/). Natural products were the earliest chemical agents of anesthesia, although acupuncture was in use as a mechanical device in China as early as 2200 BCE. The natural products included extracts of opium poppy found in Sumerian artifacts (4000 BCE), cannabis used in India in 600 BCE, and ultimately the isolation of a pure compound by Sertü rner from opium in 1805 that he named morphine (Figure 1 ). Even the arrow poison curare has been used as a muscle-relaxing anesthetic. In parallel, low-molecular-weight volatile compounds able to induce loss of consciousness were explored. The alchemist Paracelsus is thought to have used diethyl ether on animals in the 16 th century, while Humphrey Davy, the physician noted for use of digitalis extracts for congestive heart failure (''dropsy'' in contemporary parlance), advocated for nitrous oxide in 1800. Chloroform was used by John Snow on Queen Victoria of England to manage the pain of childbirth in the 1850s (Caton, 2000) . This was the same John Snow who famously traced a cholera epidemic to the village pump and launched the discipline of epidemiology in public health.
Particularly famous in the annals of anesthesiology was the use of (diethyl-) ether by Dr. W.T.G. Morton at Massachusetts General Hospital in 1846 for a surgical procedure. The operating amphitheater was known subsequently as the ''ether dome'' (Fenster, 2001 (Meyer and Wiener-Kronish, 2014) .
Thiopental is in the chemical class of thiobarbituates, the sulfur analog of pentobarbital. It acts as a sedative, anesthetizing by central nervous system depression. Over 5 decades of use as an intravenous anesthetic from the 1930s into the 1980s, thiopental was observed to have a range of side effects, including slowed breathing (respiratory depression), cardiac arrhythmias, prolonged sleepiness, headache, nausea, and slow recovery of full conscious acuity. These delayed recovery effects were in part due to tissue accumulation and slow metabolic excretion. Central respiratory depression is used in euthanasia protocols in countries such as Belgium and the Netherlands. Thiopental induces coma, and then pancuronium bromide is injected as a muscle paralytic agent to stop breathing.
Given the side effects of thiopental, there was room for a faster acting and safer intravenous anesthetic. Propofol was developed to meet this need by John Baird Glen, who is being honored by the 2018 LaskerDeBakey Clinical Medical Research Award. Approved in the late 1980s, this intravenous anesthetic has been used over the past 30 years in an average of 30-50 million patients per year in the USA and in 90 other countries around the globe. One of the criteria for the LaskerDeBakey Award is to improve the lives of many patients. Propofol indisputably qualifies as it has been used in perhaps a billion human surgeries since its clinical introduction.
John Baird Glen and the Invention of Propofol
Over a 30-year period beginning in the 1970s, James Baird Glen championed use of propofol as a novel, safe IV anesthetic working in the United Kingdom at Imperial Chemical Industries (ICI, which became Zeneca, which in turn became Astra Zeneca). Glen began his career as an animal veterinarian and an academic at the University of Glasgow, where he developed expertise in anesthesia in various animal species. To enhance his ability to analyze novel anesthetics with desirable characteristics such as fast onset and recovery, Glen moved to the pharmaceutical branch of ICI. ICI had developed the inhaled anesthetic halothane ( Figure 1A ) and thus had an infrastructure devoted to that therapeutic arena. With his animal pharmacology skills, Glen was the perfect biology colleague for medicinal chemists analyzing synthetic chemical frameworks for new agents. Work initiated in 1973 and reported in 1980 (James and Glen, 1980) laid the groundwork for a revolution in patient care. Among a series of alkylsubstituted phenols, dramatically pedestrian structures for therapeutic agents, they found that 2,6-diethylphenol had ''hypnotic'' activity in animals but had slow kinetics of onset. Glen scoured the ICI chemical collection and settled on the related, bulky 2,6-diisopropoxy compound, previously analyzed for antibacterial activity, that became propofol ( Figure 1A) . In a series of animal tests optimized from his veterinary background, Glen observed that this molecule had a unique balance of anesthesia with minimal effects on respiration and heart rate. It could be given repeatedly with fast recovery time and no accumulated ''hangover'' effect in mouse studies, suggesting fast metabolism. Subsequent pharmacokinetic and metabolic studies in animals and then humans showed fast onset of anesthesia and >99% hepatic metabolism. About 50% of a human dose is converted to the water-soluble compound glucuronide that is excretable by the kidneys. The remainder is oxygenated by hepatic P450 enzymes and then sulfated to again create water-soluble, excretable, inactive metabolites ( Figure 1A ).
The Long Search for an Acceptable Formulation Propofol seemed to have a bright future but presented monumental formulation challenges, resulting from the fact that 2,6-di-isopropylphenol is an oil at room temperature and is barely soluble in water. The pKa of the phenol is about 11, meaning that less than 0.1% is ionized at physiologic pH. The octanol: water distribution is reported as 6,761:1 (with logP = 4.0; Lemaitre et al., 2015) , so the molecule is practically insoluble in and immiscible with aqueous solutions. The available technology for formulation of water insoluble oils in the 1970s relied on cremophor, a polyethoxylated castor oil component. While propofol retained its rapid onset and recovery pharmacokinetics as an anesthetic agent in a cremophor mixture, Glen and colleagues observed occasional anaphylactic responses in pigs and subsequently in early human trials. In the face of these liabilities, ICI management wanted to shut the project down. Glen, however, believing the anaphylaxis was due only to the cremophor, persisted in searching for safer, efficacious vehicles.
In a review article, Baker and Naguib (2005) noted that propofol presented challenges that were distinct from previous synthetic anesthetics. In contrast to sodium pentothal (Figure 1) , which it eventually replaced in anesthetic practice, propofol does not have any functional groups, allowing it to be converted to an aqueous soluble salt. It was therefore the development of advanced emulsion formulation technologies in the early 1980s that allowed Glen to crack the formulation barrier.
Stable emulsions with droplet sizes small enough to pass through filters to remove microbes and enter capillary beds without generating emboli (0.15-0.3 microns, approximately the size of chylomicrons) could be created using high shear microemulsifiers. In 1981, Glen tested a vehicle containing egg lecithin and soybean oil as solubilizers. This formulation worked in pigs without any anaphylactic side effects and led to the clinical testing of propofol under the trade name Diprivan, an emulsion with 1% propofol, 0.005% EDTA, soybean oil (100 mg/mL), egg lecithin (12.5 mg/mL), and glycerol (22.5 mg/mL), pH adjusted to 7 to 8.5 (US pharmacopeia guidelines). Baker and Naguib (2005) note that the soybean oil dissolves the propofol, glycerol is present to maintain isotonicity with blood, and egg lecithin provides an emulsion in which the propofol-soybean droplets are stable. In vivo, the propofol diffuses from the oil droplets into the blood stream and then into cell membranes with rapid equilibration with brain neurons in less than a minute. Small droplets mean large surface area for rapid diffusion out of the soybean oil droplets. The size range of the stable droplets in Diprivan vials refract light and create a milky color. Hence the sobriquet ''milk of amnesia'' (Euliano and Gravenstein, 2004) . This is a word play on the venerable antacid and laxative product Milk of Magnesia, which is a slurry of the simple inorganic compound magnesium hydroxide (Mg(OH) 2 ). Absent Glen's convictions that propofol would be an intervention that both patients and anesthesiologists would value for rapid action followed by clear-headed recovery from surgery and minimal postoperative nausea, the molecule would not have emerged from the ICI development group. Approved in the UK in 1987 and in the USA and some 90 other countries in 1989, propofol has become the dominant and standard agent for induction of anesthesia and brought a true sea-change to the practice of ambulatory surgery globally. Glen continued into the 1990s to provide algorithms and devices for control of continuous infusion of propofol for sedation in critical care patients, leading to substantial replacement of inhalational anesthesia around the world.
Because of the stringent chemistry, manufacturing, and control requirements along with reported low profit margins, there are few manufacturers for propofol despite the enormous volume used globally. Shortages were reported in some of the 15,000 hospitals and clinics in the USA in 2017, when 30-50 million doses were dispensed.
Despite its undeniable benefit, use of propofol is not without controversy. No essay on propofol would be complete without mention that this was the agent that Michael Jackson took/was administered in his fatal efforts to treat insomnia in 2009, highlighting that the compound must be used safely. Separately, European manufacturers have refused to sell propofol to states in the USA that wanted to use it as part of a cocktail in administration of the death penalty.
How Propofol and Other Small
Molecule Anesthetics Work: The Mystery of Consciousness Early views on propofol's mechanism of action focused on general disruption of membrane function rather than specific molecular targets given the simplicity of the chemical structure. However, more recent work has centered on propofol and related molecules as ligands for pentameric ligand-gated ion channels such as the glycine and GABA receptors along with nicotinic acetylcholine receptors (Nury et al., 2011) . X-ray structures of complexes with either propofol or the smaller desflurane anesthetic with a bacterial homolog of the pentameric GABA A channel revealed an inner membrane pocket in each protein monomer that could bind propofol or the smaller desflurane at the extracellular end of the transmembrane domain a helices (Tang and Eckenhoff, 2018) . Indeed, the GABA receptor/ion channel is the site of multiple anesthetic and relaxant molecular classes ( Figure 1B ; Lovinger, 2008) . In many operations, propofol is used as an induction anesthetic and then isoflurane or desflurane as a follow on inhalation drug for moment-to-moment titration. Anesthetic binding agonizes the GABA A -and glycine-gated ion channels and potentiates their inhibitory activity. In addition, modern transcriptomic and proteomic analyses have suggested multiple additional targets for propofol and other general anesthetics, an as-yet-uncertain functional promiscuity, not unexpected from the simple structures of these small hydrophobic molecules (Tang and Eckenhoff, 2018) .
From the dawn of anesthetic use, the ability of these molecules, especially the simple synthetic ones exemplified in Figure 1 , to render humans unconscious has been both remarkable and mysterious. A central unsolved question is how binding of anesthetics to such ligandgated ion channels in the brain leads to loss of consciousness. Indeed, these molecules may be the best tools for experimental attack on the consciousness conundrum. It has been said that if we do not understand consciousness, how can we comprehend the mechanisms by which it goes away and then returns? Yet, this is an intense area of current investigation using regional electroencephalogram (EEG) sensors and fMRI scans to evaluate whether anesthesia reflects a loss of synchrony in signaling between different regions of the cortexthe outermost layer of the brain important in attention, awareness, thought, and memory (Liu et al., 2012 (Liu et al., , 2013 Wollstadt et al., 2017) . Anesthesia by propofol seems to prevent the electrical spreading of signals in the cortex seen in periods of wakefulness/consciousness. It is therefore likely that small molecule anesthetics may be the probes that ultimately allow unraveling of the conscious/unconscious states of the brain.
Among the several ways one can appreciate the impact of the determined efforts of James Glen over much of his professional career to discovery, preclinical and clinical development, and approval of propofol, two are fitting end notes. The first is that anyone who has had a periodic preventive colonoscopy in the last decade and been fully awake and alert minutes later can thank propofol. The second is a quote from Linda Geddes in the November 23, 2011, issue of New Scientist (Geddes, 2011): ''My experience leaves me with a renewed sense of awe for what anaesthetists do as a matter of routine. Without really understanding how, they guide hundreds of millions of people a year as close to the brink of nothingness as it is possible to go without dying. Then they bring them safely back home again.''
